Want to see STXS full AI Analyst Report?
Top Page
Stereotaxis
(STXS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.00
▼(-1.48% Downside)
Action:Reiterated
Date:07/09/26
The score is held down primarily by weak financial performance—large, persistent losses and substantial free-cash-flow burn with modestly declining TTM revenue. Technicals are mixed with the stock still below key longer-term moving averages, limiting momentum support. Offsetting factors include constructive FY2026 growth guidance and strong product/regulatory catalysts highlighted on the earnings call, but execution and cash runway risks keep the overall rating below average.
Positive Factors
Multiple regulatory approvals expanding addressable market
Multiple FDA clearances (MAGIC PMA, Synchrony clearance, Genesys X clearance) materially broaden the product ecosystem and increase path-to-commercial scale. Regulatory authorizations lower adoption barriers, enable capital and consumable sales across geographies, and support durable revenue diversification over time.
Negative Factors
Large, persistent cash burn
Sustained negative operating and free cash flow materially increases financing risk and can force dilution or punitive financing terms. Until recurring disposables and system placements scale meaningfully, ongoing cash burn constrains strategic flexibility and elevates long‑term funding requirements.
Read all positive and negative factors
Positive Factors
Negative Factors
Multiple regulatory approvals expanding addressable market
Multiple FDA clearances (MAGIC PMA, Synchrony clearance, Genesys X clearance) materially broaden the product ecosystem and increase path-to-commercial scale. Regulatory authorizations lower adoption barriers, enable capital and consumable sales across geographies, and support durable revenue diversification over time.
Read all positive factors
Stereotaxis (STXS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$166.15M
Dividend YieldN/A
Average Volume (3M)583.61K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue Growth13.40%
EPS Growth20.97%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-0.25
Shares Outstanding97,736,700
10 Day Avg. Volume380,338
30 Day Avg. Volume583,610
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue5.28
Enterprise Value/Gross Profit9.80
Enterprise Value/Ebitda-8.20
Forecast
1Y Price Target
$4.13Price Target Upside103.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$39.40M
Stereotaxis Business Overview & Revenue Model
Company Description
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN...
How the Company Makes Money
Stereotaxis generates revenue primarily by selling and supporting its robotic magnetic navigation systems installed in hospitals and electrophysiology labs. A key recurring component of its model comes from procedure-driven sales of related consum...
Stereotaxis Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call balanced transformational strategic progress with near-term execution and financial headwinds. Major positives include multiple recent FDA approvals (MAGIC, Synchrony), successful early clinical use of the MAGIC catheter, a clear disposable revenue opportunity (disposables often >$5k–$8k per procedure), Genesys X and Synchrony commercialization steps, and the Robocath acquisition that strengthens long-term robotics strategy. Offsetting these are short-term declines in reported revenue (Q1 revenue down ~16%), capacity constraints and supply transition issues due to winding down the Johnson & Johnson relationship, continued operating losses, and increasing negative free cash flow. Management reiterated >$40M revenue guidance for 2026 and described a path to ramp and profitability, but achieving that depends on manufacturing ramp, adoption of disposables, and execution of capital sales.Positive Updates
Major Regulatory Approvals
Received multiple recent regulatory approvals including 4 U.S. FDA approvals in recent months (PMA for MAGIC in January; FDA clearance for Synchrony last month), plus approvals in Europe and China. Genesys X previously received FDA clearance. These approvals create a new foundational ecosystem of products and materially expand the company's addressable market.
Negative Updates
Quarterly Revenue Decline
Q1 2026 revenue was $6.3 million versus $7.5 million in Q1 2025, a decline of approximately 16.0%. System revenue fell from $2.0 million to $1.3 million (-35.0%) and recurring revenue declined from $5.5 million to $5.0 million (-9.1%).
Read all updates
Q1-2026 Updates
Positive
Negative
Major Regulatory Approvals
Received multiple recent regulatory approvals including 4 U.S. FDA approvals in recent months (PMA for MAGIC in January; FDA clearance for Synchrony last month), plus approvals in Europe and China. Genesys X previously received FDA clearance. These approvals create a new foundational ecosystem of products and materially expand the company's addressable market.
Read all positive updates
Company Guidance
Management reiterated guidance for double‑digit revenue growth in FY2026 with annual revenue expected to surpass $40 million, ramping sequentially each quarter and with both Q3 and Q4 forecasted to exceed $10 million; they also expect at least $3 million of Synchrony revenue this year and to establish at least five active Genesis programs. Operational targets include ramping MAGIC catheter production to about 500 units per month by year‑end and capturing disposable revenue per procedure already >$5,000 and often >$8,000 (including a recent $100,000 hospital disposables order for a month). Quarterly and balance‑sheet metrics cited alongside the guidance were Q1 revenue of $6.3 million (system $1.3M, recurring $5.0M), gross margin 60% (recurring 66%, system 39%), operating loss $6.0M (net loss $5.9M), adjusted operating loss $2.9M, negative free cash flow $3.5M, and cash of $14.6M with no debt; management said operating losses should decline as recurring revenue grows and that they can integrate Robocath and fund the ramp without substantial dilution.Stereotaxis Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.20M | 32.38M | 26.92M | 26.77M | 28.15M | 35.02M |
| Gross Profit | 16.80M | 17.07M | 14.59M | 14.86M | 18.47M | 23.23M |
| EBITDA | -20.09M | -20.09M | -23.08M | -20.12M | -17.86M | -10.60M |
| Net Income | -21.68M | -21.64M | -24.05M | -20.71M | -18.29M | -10.72M |
Balance Sheet | ||||||
| Total Assets | 54.03M | 52.25M | 46.72M | 41.91M | 53.41M | 60.98M |
| Cash, Cash Equivalents and Short-Term Investments | 14.62M | 13.42M | 12.22M | 19.82M | 28.43M | 38.74M |
| Total Debt | 5.28M | 5.44M | 6.01M | 5.49M | 5.86M | 6.11M |
| Total Liabilities | 34.43M | 33.53M | 35.29M | 19.99M | 21.48M | 21.56M |
| Stockholders Equity | 19.60M | 18.72M | 11.43M | 21.92M | 31.93M | 39.42M |
Cash Flow | ||||||
| Free Cash Flow | -15.52M | -13.78M | -8.53M | -9.51M | -10.79M | -4.34M |
| Operating Cash Flow | -15.35M | -13.69M | -8.50M | -9.14M | -8.41M | -2.95M |
| Investing Cash Flow | -172.00K | -93.00K | 74.00K | 19.77M | -22.09M | -1.40M |
| Financing Cash Flow | 19.45M | 14.76M | 297.00K | 81.00K | 220.00K | 547.00K |
Stereotaxis Technical Analysis
Negative
2.03
Price Trends
1.84
Negative
1.91
Negative
2.25
Negative
Market Momentum
-0.03
Negative
42.64
Neutral
41.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Negative. The current price of 2.03 is above the 20-day moving average (MA) of 1.77, above the 50-day MA of 1.84, and below the 200-day MA of 2.25, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 42.64 is Neutral, neither overbought nor oversold. The STOCH value of 41.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STXS.
Stereotaxis Risk Analysis
Stereotaxis disclosed 57 risk factors in its most recent earnings report. Stereotaxis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stereotaxis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $1.74B | -350.51 | -0.95% | ― | 15.01% | 88.10% | |
73 Outperform | $2.35B | 37.22 | 16.19% | 0.95% | 13.27% | 36.99% | |
68 Neutral | $4.38B | 31.25 | 8.95% | ― | 11.34% | 12.26% | |
56 Neutral | $1.38B | -66.10 | -6.07% | ― | 4.03% | 70.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $166.15M | -6.96 | -153.21% | ― | 13.40% | 20.97% | |
45 Neutral | $33.78M | -6.84 | -166.28% | ― | 3.37% | 15.78% |
* Healthcare Sector Average
STXS
Stereotaxis
1.70
-0.57
-25.11%
ATRC
Atricure
34.28
2.98
9.52%
LMAT
Lemaitre Vascular
102.74
19.42
23.30%
MMSI
Merit Medical Systems
73.44
-20.01
-21.41%
STAA
Staar Surgical
27.76
10.46
60.46%
MLSS
Milestone Scientific
0.38
-0.27
-41.38%
Stereotaxis Corporate Events
Business Operations and StrategyM&A Transactions
Stereotaxis Advances Vascular Robotics with Robocath Acquisition
Positive
Jul 9, 2026
On July 7, 2026, Stereotaxis completed its previously announced approximately $20 million acquisition of French vascular robotics company Robocath, issuing common shares and pre-funded warrants as consideration and as partial payment to Robocath&#...
Executive/Board ChangesShareholder Meetings
Stereotaxis Shareholders Endorse Board, Auditor and Compensation
Positive
May 15, 2026
On May 14, 2026, Stereotaxis held its Annual Meeting of Shareholders with approximately 65.34% of the 121,182,983 total voting power represented, satisfying quorum requirements. Shareholders voted on the election of three Class I directors to serv...
Business Operations and StrategyM&A Transactions
Stereotaxis to Acquire Robocath in Strategic Robotics Deal
Positive
Apr 15, 2026
On April 14, 2026, Stereotaxis agreed to acquire 100% of French robotic cardiology innovator Robocath in a deal expected to close in July 2026, subject to debt restructuring, French regulatory clearance, and other customary conditions. The upfront...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.